Thromboprophylaxis during chemotherapy in patients with advanced cancer

Thrombosis Research

Volumn 125, Issue , 2010, Pages S17-S20

  Agnelli, Giancarlo ^a   Verso, Melina ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

anticancer therapy; Cancer; Chemotherapy; Deep venous thrombosis; Pulmonary embolism; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; NADROPARIN;

ARTICLE; HUMAN; LUNG EMBOLISM; NEOPLASM; RANDOMIZED CONTROLLED TRIAL; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; HUMANS; NADROPARIN; NEOPLASMS; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VENOUS THROMBOEMBOLISM;

EID: 77955493111     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/S0049-3848(10)70007-4     Document Type: Article

References (38)

1. Heit, JA, Mohr, DN, Silverstein, MD, Petterson, TM, O'Fallon, WM, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 160 (2000), 761–768.
2. Bloom, JW, Doggen, CJ, Osanto, S, Rosendaal, FR, Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293 (2005), 715–722.
3. Levitan, N, Dowlati, A, Remick, SC, Tahsildar, HI, Sivinski, LD, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy vs. those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 78 (1999), 285–291.
4. Thodiyil, PA, Kakkar, AK, Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost 87 (2002), 1076–1077.
5. Chew, HK, Wun, T, Harvey, D, Zhou, H, White, RH, Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166 (2006), 458–464.
6. Haddad, TC, Greeno, EW, Chemotherapy-induced thrombosis. Thromb Res 118 (2006), 555–568.
7. Prandoni, P, Falanga, A, Piccioli, A, Cancer and thromboembolism. Lancet Oncol 6 (2005), 401–410.
8. Stein, PD, Beemath, A, Meyers, FA, Kayali, F, Skaf, E, et al. Pulmonary embolism as cause of death in patients who died with cancer. Am J Med 119 (2006), 163–165.
9. Shen, VS, Pollak, EW, Fatal pulmonary embolism in cancer patients: is heparin prophylaxis justified?. South Med J 73 (1980), 841–843.
10. Khorana, AA, Francis, CW, Culakova, E, Lyman, GH, Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24 (2006), 484–490.
11. Sorensen, HT, Mellemkjaer, L, Olsen, JH, Baron, JA, Prognosis in cancers associated with venous thromboembolism. N Engl J Med 343 (2000), 1846–1850.
12. Khorana, AK, Kunderer, NM, Culakova, E, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111 (2008), 4902–4907.
13. Otten, HM, Mathijssen, J, Ten Cate, H, Socsan, M, Inghels, M, et al. Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon. Arch Intern Med 164 (2004), 190–194.
14. Levine, MN, Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost 78 (1997), 133–136.
15. Goodnough, L, Saito, A, Manni, A, Increased incidence of thromboembolism in stage IV breast cancer patients treated with five-drug chemotherapy regimen: a study of 150 patients. Cancer 78 (1984), 133–136.
16. Deitcher, SR, Gomes, MP, The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 101:3 (2004), 439–449.
17. Weijl, II, Rutten, M, Zwinderrman, A, Keizer, J, Nooy, M, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 18:10 (2000), 2169–2175.
18. Numico, G, Garrone, D, Dongiovanni, V, Silvestris, N, Colantonio, I, et al. Prospective evaluation of major vascular events in patients with non small cell lung carcinoma treated with cisplatin and gencitabine. Cancer 103:5 (2005), 994–999.
19. Priest, J, Ramsay, N, Latchaw, R, LockMan, L, Hasegawa, D, et al. Thrombotic and hemorragic stroke complicating early therapy for childhood acute lymphoblastic leukemia. Cancer 46:7 (1980), 1548–1554.
20. Gugliotta, L, Mazzucconi, M, Leone, G, Mattioli-Belmonte, M, Defazio, D, et al. Incidence of thrombotic complication in adult patients with acute lymphoblastic leucemia receiving L-asparaginase during induction therapy. Eur J Haematol 49 (1992), 63–66.
21. Rajkumar, S, Rayman, S, Gertz, M, Dispensieri, A, Lacy, M, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 20 (2002), 4219–4223.
22. Zangari, M, Anaisse, E, Barlogie, B, Brados, A, Desikan, R, et al. Increased risk of deep vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98 (2001), 1614–1615.
23. Zangari, M, Barlogie, B, Anaisse, E, Saghafifar, F, Eddlemon, P, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126 (2004), 715–721.
24. Falanga, A, Marchetti, M, Venous Thromboembolism in the Hematologic Malignancies. J Clin Oncol 27 (2009), 4848–4857.
25. Hurwitz, H, Fehrenbacher, L, Novotny, W, Cartwright, T, Hainsworth, J, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004), 2335–2342.
26. Shah, M, Ilson, D, Kelsen, DP, Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 23:1 (2005), 2574–2576.
27. Rugo, H, Bevacizumab in the treatment og breast cancer: rationale and current dataM. Oncologist 9:suppl 1 (2004), 43–49.
28. Herbst, R, Sandler, A, Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?. Oncologist 9:suppl 1 (2004), 19–26.
29. Dusenbery, K, McGuire, W, Holt, P, Carson, L, Fowler, J, et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiot Oncol Biol Phys 29 (1994), 1079–1084.
30. Levy, R, Liu, P, Greer, B, Robinson, W III, Chang, P, et al. Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIBIVA carcinoma of the cervix: a Southwest oncology group study. Gynecol Oncol 95 (2004), 145–151.
31. Wun, T, Law, L, Harvey, D, Sierack, B, Scudder, S, Ryu, J, Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation and erythropoietin. Cancer, 98(7), 2003 15: 4–20.
32. Vansteenkiste, J, Pirker, R, Massuti, B, Barata, F, Font, A, et al. Double-blind, placebo-controlled, randomized phase III trial od darbopoietin alfa in lung cancer patients. J Natl Cancer Inst 94:16 (2002), 1211–1220.
33. Levine, M, Hirsh, J, Gent, M, et al. Double blind randomized trial of very-low-dose warfarin for the prevention of thromboembolism in stage IV breast cancer. Lancet 343 (1994), 886–889.
34. Haas, SK, Kakkar, AK, Kemkes-Matthes, B, et al. Prevention of venous thromboembolism with low molecular weight heparin in patients with metastatic breast or lung cancer-results of the TOPIC studies. J Thromb Haemost, 3(Suppl 1), 2005 abstract OR059.
35. Perry, JR, Rogers, L, Lapierre, J, et al. A phase IIII randomised placebo controlled trial of thromboprophylaxis using dalteparin low molecular weight heparin in patients with newly diagnosed malignant glioma. Proceedings ASCO, 2007 abstract 2011.
36. Lyman, G, Khorana, AA, Falanga, A, et al. American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 34 (2007), 1–16.
37. Geerts, WH, Bergqvist, D, Pineo, GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 133 (2008), 381S–453S.
38. Agnelli, G, Gussoni, G, Bianchini, C, et al. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 10 (2009), 943–949.